Calidi Biotherapeutics, Inc. (CLDI) Form 8-K — Jun 23, 2026
$CLDIForm 8-KItems 5.02, 7.01, 8.01, 9.01Filed Jun 23, 2026, 8:30 AM ET0001493152-26-029710Original filing
Calidi Biotherapeutics appointed Dr. Corazon (Corsee) Sanders as a Class III director with a term expiring at the Company's 2029 annual meeting. Dr. Sanders brings over 30 years of global leadership experience in drug development, including roles at Genentech/Roche where she contributed to the approval of multiple therapies and Juno Therapeutics where she helped develop Breyanzi.
Price after filing
1 day: +0.6%7 days: +9.0%30 days: -32.3%
Close on the filing date to close N calendar days later (from $0.16). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.